Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells

Yazad Irani(Flinders University), Agnes S. M. Yong(South Australia Pathology), Naranie Shanmuganathan(South Australia Pathology), David M. Ross(South Australia Pathology), Jade Clarson(Royal Adelaide Hospital), David T Yeung(South Australia Pathology), Chung Hoow Kok(South Australian Health and Medical Research Institute), Amy Hughes(Royal Adelaide Hospital), Timothy P. Hughes(South Australia Pathology), Deborah L. White(ANZCHOG)
British Journal of Haematology
April 30, 2020
10.1111/bjh.16718
Cited by 77

Related Papers

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
|Blood|2013|705
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
|Leukemia|2012|440
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
|Leukemia|2012|417